The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis

Rheumatology

Volumn 46, Issue 7, 2007, Pages 1096-1101

  Wilson, E C F ^a   Jayne, D R W ^b   Dellow, E ^c   Fordham, R J ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Aspreva Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Cost utility analysis; Cyclophosphamide; Economic evaluation; Flare; Lupus; Lupus nephritis; Mycophenolate mofetil; Rationing; Resource; Systemic lupus erythematosus

Indexed keywords

ACICLOVIR; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; GOSERELIN; MESNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; ONDANSETRON; PREDNISOLONE; VITAMIN D;

ARTICLE; BONE DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DRUG COST; DRUG EFFICACY; ESOPHAGUS DISEASE; EVIDENCE BASED MEDICINE; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MYCOSIS; OVARY DISEASE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; SIMULATION; VOMITING;

ACUTE DISEASE; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DAY CARE; DRUG COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MODELS, ECONOMIC; MYCOPHENOLIC ACID; PREDNISOLONE; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE;

EID: 34447294549     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem054     Document Type: Article

References (30)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-24.
2. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006;8:R182.
3. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
4. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005;10:504-10.
5. Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC. Treatment for lupus nephritis. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD002922. DOI: 10.1002/14651858.CD002922.pub2.
6. Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004,.50:3934-40.
7. Chan TM. Lupus nephritis: Induction therapy. Lupus 2005;14(Suppl. 1):S27-32.
8. Mehta DK, Martin J, Costello I et al. eds. British National Formulary 49. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2005.
9. British Colombia Cancer Agency. Mesna. www.bccancer.bc.ca/HP/ drugdatabase/drugindexpro/mesna.htm (last accessed 15 January 2007).
10. Briggs A, Claxton K, Sculpher M. Further Developments in decision analytic models for economic evaluation. In: Gray A, Briggs A, eds. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006;58-65.
11. Gourley MF, Austin HA 3rd, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Mad 1996;125:549-57.
12. Guillevin L, Jarrousse B, Lok C et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomised trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991;18:567-74.
13. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
14. Wiesel M, Carl S. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group. J Urol 1998;159:28-33.
15. European Mycophenolate Mofetil Cooperative Study Group.Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-5.
16. Curtis L, Netten A. Unit Costs of Heath and Social Care 2005. Kent: Personal Social Services Research Unit, University of Kent at Canterbury, 2005.
17. Department of Health. NHS reference costs 2005. www.dh.gov.uk/ Publications AndStatistics/Publications/PublicationsPolicyAndGuidance/ PublicationsPolicyAnd GuidanceArticle/fs/ en?CONTENT_ID=4133221&chk=TxHkqo (last accessed 15 January 2007).
18. Tufts New England Medical Center. The Cost Effectiveness Analysis Registry. Preference Weights 1998-2001. www.tufts-nemc.org/cearegistry/ data/docs/phasell preferenceweights.pdf (last accessed 15 January 2007).
19. Smith KJ, Roberts MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. Am J Med 2000;108:723-9.
20. Smith KJ, Roberts MS. Antiviral therapies for herpes zoster infections. Are they economically justifiable? Pharmacoeconomics 2000; 18:95-104.
21. Balk EM, Zucker DR, Engels EA, Wong JB, Williams JW Jr, Lau J. Strategies for diagnosing and treating suspected acute bacterial sinusitis: A cost-effectiveness analysis. J Gen Intern Med 2001;16:701-11.
22. Smith KJ, Roberts MS. Cost effectiveness of newer antiviral agents for herpes zoster: Is the evidence spotty?. J Infect Dis 1998;178(Suppl. 1):S85-90.
23. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Economic evaluation using patient-level data. In: Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL, eds. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford: Oxford Untversrty Press, 2005;258-67.
24. Clarke A. Economic impact of lupus. Am J Manag Care 2001;7(Suppl):S496-S501.
25. Clarke AE, Bloch DA, Danoff DS, Esdaile JM. Decreasing costs and improving outcomes in systemic lupus erythematosus: Using regression trees to develop health policy. J Rheumatol 1994;21:2246-53.
26. Clarke AE, Penrod J, St Pierre Y et al. Underestimating the value of women: Assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol 2000;27:2597-604.
27. Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology 2001; 40:37-47.
28. McInnes PM, Schuttinga J, Sanslone WR, Stark SP, Klippel JH. The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide. Arthritis Rheum 1994;37.,1000-6.
29. Cross J, Dwornoa A, Andrews P et al. Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephrol J Clin Pract 2005;100:c92-100.
30. Aspreva Pharmaceuticals Ltd. A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subjects with lupus nephritis. www.clinicaltrials.gov/ct/show/NCT00121082 (last accessed 15 January 2007).